If you've been told your Lantus SoloStar pen is backordered and your prescriber has floated Tresiba as an option, you probably have two questions: is it actually similar enough to work, and what will it cost you. Both are fair questions, and the answers aren't identical for every patient.
This guide compares Tresiba and Lantus directly — dosing, cost, insurance coverage, and patient assistance eligibility — so you can have a specific, informed conversation with your prescriber instead of guessing at the pharmacy counter.
1. Why Tresiba Is a Common Lantus Backup
Lantus SoloStar pens have been in intermittent short supply through much of 2026, a demand shock that traces back to the December 2025 discontinuation of Semglee, the interchangeable biosimilar that had absorbed a large share of the glargine market. As patients shifted back to brand Lantus almost overnight, pen supply couldn't keep pace in every region.
Tresiba wasn't part of that demand shift and has remained consistently available. It's also a once-daily basal insulin with a long track record, which makes it a natural option for prescribers looking for an in-stock alternative rather than a completely different insulin regimen.
Tresiba is manufactured by Novo Nordisk, a different company than Sanofi (which makes Lantus) or Eli Lilly (which makes Basaglar and Rezvoglar). That means its savings programs, patient assistance program, and formulary status are handled separately from any glargine product you may have used before.
2. How Tresiba and Lantus Actually Differ
Tresiba and Lantus are both classified as long-acting basal insulins, but they are not the same drug and don't behave identically in the body.
- Active ingredient: Tresiba is insulin degludec; Lantus is insulin glargine. They are different molecules, not brand names for the same compound.
- Duration of action: Tresiba has a longer, flatter action profile — often described as lasting up to 42 hours — compared to roughly 24 hours for Lantus.
- Concentration options: Tresiba is available in both U-100 and U-200 formulations. Lantus is U-100 only.
- Formulations: Tresiba comes in FlexTouch prefilled pens and vials. Lantus comes in SoloStar pens and vials.
- Interchangeability status: Neither the FDA nor pharmacists treat Tresiba and Lantus as interchangeable. A new prescription is always required to switch between them.
3. Side-by-Side Comparison Table
| Feature | Tresiba | Lantus |
|---|---|---|
| Active ingredient | Insulin degludec | Insulin glargine |
| Manufacturer | Novo Nordisk | Sanofi |
| Concentrations | U-100 and U-200 | U-100 only |
| Formulations | FlexTouch pen, vial | SoloStar pen, vial |
| Duration of action | Up to ~42 hours | ~24 hours |
| 2026 supply status | Broadly available | SoloStar pens intermittently backordered |
| Generic/biosimilar available? | No, as of 2026 | Biosimilars exist (Semglee discontinued; Basaglar, Rezvoglar remain) |
| Commercially insured savings cap | As low as $35/month | As low as $35/month |
| Medicare Part D out-of-pocket cap | $35/month (federal insulin cap) | $35/month (federal insulin cap) |
| Uninsured cash price (before discounts) | ~$146 (FlexTouch) / ~$477 (vial) | Lower list price after 2024 cut |
4. Dose Conversion: What Changes
Because Tresiba and Lantus are different molecules with different duration profiles, dose conversion is a clinical decision your prescriber makes, not a fixed formula you can calculate yourself.
| Switching From | Typical Starting Point | What to Confirm |
|---|---|---|
| Lantus U-100 | Often same unit dose to start | Blood glucose monitoring for the first 1–2 weeks; your prescriber may adjust based on response |
| Basaglar or Rezvoglar (U-100) | Often same unit dose to start | Same as above — confirm with your prescriber before your first injection |
| Toujeo (U-300) | Not a direct unit conversion | Requires prescriber-calculated dose adjustment due to concentration difference |
Never switch your insulin dose on your own. Even though many patients start Tresiba at the same unit number they used on Lantus, your prescriber may adjust the dose based on your blood sugar patterns, kidney function, or other medications. Confirm your exact starting dose before your first Tresiba injection.
5. Cost Comparison
Sticker price and out-of-pocket cost are two different things for both of these insulins. Here's how the numbers actually break down.
| Payer Situation | Tresiba | Lantus |
|---|---|---|
| Commercially insured, using savings card | As low as $35/30-day supply | As low as $35/30-day supply |
| Medicare Part D | No more than $35/month | No more than $35/month |
| Uninsured, cash-pay program | $35 for up to a 90-day supply (Novo Nordisk Insulin Value Program) | Check Sanofi's Valyou Savings Program for current terms |
| Uninsured, no discount | ~$146 (FlexTouch) to ~$477 (vial) | Lower after 2024 list price cut, still hundreds without a discount |
Before you assume a price, run both products through a drug price checker for your specific pharmacy — cash prices and discount card rates vary more than manufacturer list prices suggest.
6. Insurance Coverage & Eligibility
| Insurance Situation | What to Expect |
|---|---|
| Commercial insurance | Most major plans cover Tresiba; formulary tier varies — some plans place it as Tier 1, others as a non-preferred brand requiring a higher copay. |
| Medicare Part D | Covered by most Part D plans, with the $35/month insulin cap applying regardless of deductible or coverage gap phase. See our Medicare Part D guide. |
| Medicaid | Generally covered, though state formularies vary — check your state's preferred drug list. |
| Step therapy plans | Some commercial plans require trying a glargine product first before approving Tresiba — ask your prescriber to document the Lantus supply issue if this applies to you. |
If your plan requires prior authorization or step therapy for Tresiba, don't wait until you're out of insulin to find out. See our prior authorization guide for how that process generally works, and ask your prescriber's office to note the current Lantus supply disruption as part of the request.
7. Patient Assistance Program Comparison
If cost is the barrier rather than availability, both manufacturers offer charity programs — but the details differ enough to matter.
| Program | Tresiba (Novo Nordisk) | Lantus (Sanofi) |
|---|---|---|
| Free medication for uninsured, income-eligible patients | Novo Nordisk Patient Assistance Program | Sanofi patient assistance program (separate application) |
| One-time emergency supply for financial hardship | Yes, once per calendar year | Check current Sanofi terms |
| Cash-pay cap (no insurance) | $35 for up to 90-day supply | Check current Valyou Savings Program terms |
| How to apply | NovoCare.com or 1-888-668-6444 | Sanofi's patient support line |
For full income limits, required documents, and how to apply, see our complete Patient Assistance Programs overview, and compare general savings mechanics in our manufacturer savings card guide. If you're on Medicare and unsure whether Extra Help changes your math, see our Extra Help (LIS) guide.
Important: Enrollment in a manufacturer patient assistance program for Lantus does not automatically carry over to Tresiba, or vice versa — these are two different companies running two separate programs. If you switch products, you'll need to apply to the new manufacturer's program separately.
8. Pros and Cons of Switching to Tresiba
Pros
- Currently well-stocked, with no reported 2026 supply constraints
- Comparable $35/month cap for commercially insured and Medicare Part D patients
- Longer, flatter action profile that some patients find smooths out overnight blood sugar
- Available in two concentrations (U-100, U-200), useful for patients on higher doses
- Novo Nordisk offers a once-a-year emergency supply option for financial hardship
Cons
- Not automatically interchangeable — always requires a new prescription
- Higher uninsured cash price than Lantus without a savings card
- No generic or biosimilar version exists, limiting future price competition
- Some commercial plans require step therapy or prior authorization
- Separate patient assistance program application if you were previously enrolled for Lantus
9. How to Switch, Step by Step
Check your current Lantus supply
Count how many days of insulin you have left. If you're under a week out and can't confirm your pharmacy has Lantus in stock, treat this as time-sensitive.
Call your prescriber's office
Explain that your Lantus pen is backordered and ask whether Tresiba is a reasonable option for you specifically. Your prescriber may also suggest Basaglar or Rezvoglar depending on your insurance and history.
Confirm the concentration and formulation
Make sure the new prescription specifies Tresiba U-100 or U-200, and whether you need a FlexTouch pen or a vial.
Check your insurance formulary
Call your insurer or check your online member portal to confirm Tresiba's coverage tier before you get to the pharmacy counter.
Enroll in the Tresiba savings program
If you're commercially insured or paying cash, enroll in Novo Nordisk's savings offer at NovoCare.com before your first fill to lock in the lower price.
Confirm your starting dose
Review your exact starting dose and injection timing with your prescriber or a diabetes educator before your first Tresiba injection.
10. Approval & Coverage Timelines
| Step | Typical Timeframe |
|---|---|
| New prescription sent electronically to pharmacy | Same day, if prescriber's office responds promptly |
| Insurance formulary check | Minutes to same day via your plan's online portal |
| Prior authorization, if required | 2–5 business days typically; can extend to 2 weeks with appeals |
| Novo Nordisk savings card enrollment | Immediate to same-day online |
| Novo Nordisk Patient Assistance Program application | 1–3 weeks for a complete application |
| Emergency supply request (financial hardship) | Same-day to next-day via the dedicated phone line |
11. Renewing Coverage After You Switch
- Check your Tresiba savings card's expiration terms — most manufacturer offers run through the end of the calendar year and require re-enrollment in January.
- If you enroll in the Novo Nordisk Patient Assistance Program, expect to reapply roughly every 12 months with updated income documentation.
- If your Lantus supply stabilizes later and you'd rather switch back, that also requires a new prescription — Tresiba enrollment doesn't automatically revert.
- Revisit your insurance formulary at your plan's annual open enrollment, since coverage tiers for both products can change year to year.
12. Common Mistakes When Switching
- □ Assuming a pharmacist can substitute Tresiba for Lantus without a new prescription.
- □ Not specifying U-100 vs. U-200 concentration on the new prescription.
- □ Applying your old Lantus unit dose without confirming it with your prescriber first.
- □ Assuming your Lantus patient assistance enrollment transfers automatically to Tresiba.
- □ Not checking your insurance formulary before filling, resulting in a rejected claim at the counter.
- □ Waiting until you're completely out of insulin before calling your prescriber's office.
Most of these mistakes are avoidable with one phone call — either to your prescriber's office or your insurance plan — before you show up at the pharmacy.
13. Decision Tree: Should You Switch to Tresiba?
Bring up your insurance coverage and any patient assistance enrollment so your prescriber can pick the alternative most likely to be covered and affordable for you specifically.
14. Real Patient Examples
Example 1 — Commercially insured, Lantus SoloStar unavailable: A patient's pharmacy had no SoloStar pens for two weeks straight. Their prescriber sent a new Tresiba FlexTouch prescription, the plan covered it at a similar copay, and the patient enrolled in Novo Nordisk's savings card the same day to keep the cost near $35/month.
Example 2 — Uninsured, previously on Sanofi's Lantus assistance program: This patient assumed their existing Lantus assistance enrollment would simply extend to Tresiba. It didn't — they had to submit a new application directly to Novo Nordisk's Patient Assistance Program, which took about two weeks to process.
Example 3 — Medicare Part D patient on a tight budget: Concerned about cost before switching, this patient confirmed with their Part D plan that Tresiba was covered under the standard $35/month federal insulin cap, the same as their prior Lantus copay, so the switch didn't change their monthly cost at all.
Related: Lantus Shortage 2026: What to Do & Alternatives
Full details on why the Lantus SoloStar shortage is happening and how it's being tracked.
Need help paying for insulin or diabetes meds?
Bottom Line
Tresiba is a solid, well-covered backup while Lantus SoloStar pens remain intermittently backordered — it's widely stocked, comparably priced under most insurance and Medicare Part D plans, and manufactured under a separate supply chain that isn't affected by the biosimilar demand shift driving the Lantus shortage. It is not a drop-in pharmacy substitution, though.
Confirm coverage, apply any relevant savings program, and get your exact starting dose from your prescriber before your first injection. If cost, not availability, is your main barrier, apply directly to Novo Nordisk's Patient Assistance Program rather than assuming a prior Lantus enrollment carries over.